Literature DB >> 19145376

In vitro inhibitory effect of mesenchymal stem cells on zymosan-induced production of reactive oxygen species.

A F Tsyb1, V N Petrov, A G Konoplyannikov, E V Saypina, L A Lepechina, S Sh Kalsina, I V Semenkova, E V Agaeva.   

Abstract

In vitro chemiluminescent test showed that human bone marrow mesenchymal stem cells and conditioned media dose-dependently inhibit production of reactive oxygen species by macrophages: 50% inhibition of chemiluminescence (compared to biocontrol) was observed at 1:1 mesenchymal stem cell/macrophage ratio or after addition of 20-25% conditioned media to the incubation medium. The observed mechanism of inhibition of production of reactive oxygen forms can play an essential role in the formation of local immunosuppressive microenvironment in the organism after allogenic transplantation of mesenchymal stem cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19145376     DOI: 10.1007/s10517-008-0238-8

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  4 in total

Review 1.  Lasers, stem cells, and COPD.

Authors:  Feng Lin; Steven F Josephs; Doru T Alexandrescu; Famela Ramos; Vladimir Bogin; Vincent Gammill; Constantin A Dasanu; Rosalia De Necochea-Campion; Amit N Patel; Ewa Carrier; David R Koos
Journal:  J Transl Med       Date:  2010-02-16       Impact factor: 5.531

Review 2.  Mechanisms of mesenchymal stem/stromal cell function.

Authors:  Jeffrey L Spees; Ryang Hwa Lee; Carl A Gregory
Journal:  Stem Cell Res Ther       Date:  2016-08-31       Impact factor: 6.832

Review 3.  Perivascular Mesenchymal Stem/Stromal Cells, an Immune Privileged Niche for Viruses?

Authors:  Grégorie Lebeau; Franck Ah-Pine; Matthieu Daniel; Yosra Bedoui; Damien Vagner; Etienne Frumence; Philippe Gasque
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

4.  Autologous Stromal Vascular Fraction in the Intravenous Treatment of End-Stage Chronic Obstructive Pulmonary Disease: A Phase I Trial of Safety and Tolerability.

Authors:  Kristin Comella; Jesus A Perez Blas; Tom Ichim; Javier Lopez; Jose Limon; Ruben Corral Moreno
Journal:  J Clin Med Res       Date:  2017-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.